Developing next generation kinase inhibitors for autoimmune disease & cancer|Tim Mitchell, CEO, Sareum Holdings plc 00:10:00
Dr Tim Mitchell has over 35 years’ experience in the industry with key management and business expertise gained from his positions at Cambridge Discovery Chemistry Ltd and his roles at Millennium Pharmaceuticals Research and Development Ltd as a member of the management team and in forming the integrated Structure-Based Discovery department. Prior to that, he was director of computational chemistry at Cambridge Discovery Chemistry Ltd and a team leader in the Computational and Structural Sciences department at SmithKline Beecham Pharmaceuticals.
